Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceuticals (ASX:RCE) highlights ongoing initiatives within its Anti-Infective Research (AIR) Unit situated at the Murdoch Children’s Research Institute (MCRI), Victoria
- The collaboration has been crucial in delivering positive efficacy data from RECCE 327’s pre-clinical trials against a diverse range of life-threatening infectious pathogens
- RCE last traded at 46 cents, at 10:30am AEDT
Recce Pharmaceuticals (ASX:RCE) has announced the ongoing initiatives within its Anti-Infective Research (AIR) Unit situated at the Murdoch Children’s Research Institute (MCRI) in Victoria.
“The current risk of antibiotic resistance is more severe than ever, making commercial-academic collaborations crucial for advancing antibiotic discovery,” the company wrote on Tuesday.
MCRI Director Prof. Andrew Steer cut straight to the point of the collaboration between MCRI and Recce.
“The partnership between Recce and MCRI aims to propel initiatives forward and position Australia as a leader in the battle against antibiotic resistance,” Prof. Andrew Steer Director of Infection, Immunity, and Global Health at MCRI said.
In 2023, Recce established a specialised Anti-Infective Research Unit led by Dr. Sohinee Sarkar, which focused on fostering innovation in the field of anti-infective therapeutics.
Building on these achievements, and by leveraging MCRI’s globally renowned expertise and resources, the company is actively streamlining its continuous pre-clinical programs and exploring new possibilities for future clinical trials.
The collaboration has been crucial in delivering positive efficacy data from RECCE 327’s pre-clinical trials against a diverse range of life-threatening infectious pathogens.
“Our continued work at the AIR Unit aligns with Murdoch Children’s mission to address the global health threat of anti-microbial resistance through innovative research.
“The synergy between our organisations will undoubtedly lead to ground-breaking
discoveries that have the potential to transform the landscape of infectious disease
treatment.” Recce Pharmaceuticals CEO James Graham said.
RCE last traded at 46 cents, at 10:30am AEDT.
